Results 61 to 70 of about 80,955 (206)

Regulation of poly(ADP-ribose) polymerase-1 (PARP-1) gene expression through the post-translational modification of Sp1: a nuclear target protein of PARP-1-7

, 2011
Copyright information:Taken from "Regulation of poly(ADP-ribose) polymerase-1 (PARP-1) gene expression through the post-translational modification of Sp1: a nuclear target protein of PARP-1"http://www.biomedcentral.com/1471-2199/8/96BMC Molecular Biology
Sylvain L Guérin (83633), Serge Desnoyers (83632), Steeve Leclerc (22751), Karine Zaniolo (83631)   +3 more
core   +1 more source

Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy [PDF]

, 2014
BRCA1, a key factor in homologous recombination repair may also regulate base excision repair (BER). Targeting BRCA1-BER deficient cells by blockade of ATM and DNA-PKcs could be a promising strategy in breast cancer.
Seedhouse, Claire, Russell, R, Moseley, P, Arora, A., Agarwal, D., Russell, R., Chan, Stephen, Green, A, Albarakati, N, Rakha, E.A., Abdel-Fatah, TMA, Caldas, C, Ellis, IO, Moseley, P., Rakha, Emad A., Albarakati, Nada, Doherty, Rachel, Chan, S., Perry, Christina, Seedhouse, C, Alsubhi, N., Ball, G., Moseley, Paul, Agarwal, D, Perry, C., Arora, Arvind, Alsubhi, N, Doherty, R, Arora, A, Russell, Roslin, Ball, G, Albarakati, N., Green, Andrew, Ball, Graham, Abdel-Fatah, Tarek M.A., Rakha, EA, Caldas, Carlos, Caldas, C., Ellis, I.O., Alsubhi, Nouf, Agarwal, Devika, Abdel-Fatah, T.M.A., Seedhouse, C., Chan, S, Doherty, R., Madhusudan, Srinivasan, Perry, C, Madhusudan, S, Green, A., Madhusudan, S., Ellis, Ian O.   +50 more
core   +1 more source

The results of PAPR inhibitory percentage in seven putative PARP-1 inhibitor candidates and PARP-1 inhibitor (3-AB).

, 2013
3-AB had dose-dependent PARP inhibitory effects, and the most obvious dose-dependent PARP inhibitory effect in the seven PARP inhibitor candidates was NSC747854.
Hsu-Shan Huang (381711), Chun-Liang Chen (5135), Chia-Chung Lee (381710), Dah-Shyong Yu (127126), Shih-Hwa Chiou (39111), Kuo-Feng Huang (381707), Tsung-Chih Chen (381709), Yu-Ru Lee (381705), Ya-Chun Liang (381706), Shih-Jie Chou (381708)   +9 more
core   +1 more source

BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer [PDF]

, 2017
Background: Pancreatic cancer has become the third leading cause of cancer death with minimal improvements in outcome for over 40 years. Recent trials of therapies that target-defective DNA maintenance using poly (ADP-ribose) polymerase (PARP ...
Pishvaian, Michael J., David K Chang, Christopher L Wolfgang, Wolfgang, Christopher L., Laheru, Daniel, Jonathan R Brody, Chang, David K., Daniel Laheru, Andrew V Biankin, Biankin, Andrew V., Michael J Pishvaian, Bailey, Peter, Peter Bailey, Brody, Jonathan R.   +13 more
core   +1 more source

PARP inhibitor efficacy depends on CD8+ T cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. [PDF]

, 2019
Combinatorial clinical trials of PARP inhibitors with immunotherapies are ongoing, yet the immunomodulatory effects of PARP inhibition have been incompletely studied.
Rottenberg, Sven, Guerriero, Jennifer L, Wang, Dan, Li, Michelle K, Cheney, Emily M, Kothari, Aditi, de Oliveira Taveira, Mateus, Wulf, Gerburg M, Mehta, Anita K, Jonkers, Jos, Visal, Tanvi, Shapiro, Geoffrey I, Pantelidou, Constantia, Sonzogni, Olmo, Pinto, Jocelin, Bouwman, Peter, Castrillon, Jessica A   +16 more
core   +1 more source

Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property

Scientific Reports, 2017
PARP1 trapping at DNA lesion by pharmacological inhibitors has been exploited in several cancers exhibiting defects in DNA repair mechanisms. PARP1 hyperactivation is involved in therapeutic resistance in multiple cancers.
Chandra Bhushan Prasad, Shyam Babu Prasad, Suresh Singh Yadav, Laxmi Kant Pandey, Sunita Singh, Satyajit Pradhan, Gopeshwar Narayan   +6 more
doaj   +1 more source

Poly(ADP-Ribose) Polymerase (PARP) signaling of DNA damage induced by Topoisomerase 1 (TOP1) inhibition in carcinoma cells: chemotherapeutic implications of PARP and TOP1 inhibitors.

, 2010
Una nuova strategia molecolare che incrementa l’azione antitumorale degli inibitori della Topoisomerasi 1 (TOP1) si basa sull’utilizzo di inibitori delle poli(ADP-ribosio) polimerasi (PARP).
D'Onofrio, Giovanna
core  

PARP inhibitors in ovarian cancer [PDF]

Annals of Oncology, 2016
Slow progress in improving the outcome of ovarian cancer with chemotherapy over the last decade has stimulated research into molecularly targeted therapy. Poly(ADP-ribose) polymerase (PARP) inhibitors target DNA repair and are specifically active in cells that have impaired repair of DNA by the homologous recombination (HR) pathway.
openaire   +3 more sources

Impact of PARP inhibitors on progression-free survival in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective analysis

World Journal of Surgical Oncology
Objective Poly (ADP-ribose) polymerase (PARP) inhibitors such as olaparib and niraparib have shown promise in extending progression-free survival (PFS) in patients with platinum-sensitive recurrent (PSR) epithelial ovarian cancer.
Yumei Zhou, Junfen Xu
doaj   +1 more source

Abstract 3453: Progression through mitosis promotes PARP inhibitor induced cytotoxicity in homologous recombination deficient cancer cells

, 2017
Mutations in homologous recombination (HR) DNA repair genes BRCA1 and BRCA2 predispose to tumorigenesis. HR-deficient cancers are hypersensitive to Poly (ADP ribose)-polymerase (PARP) inhibitors, but can acquire resistance and relapse.
Floris Foijer, Peter Bouwman, Marcel A. Vugt, van, Sohvi Blatter, Jos Jonkers, Sven Rottenberg, Pepijn M. Schoonen, Madalena Tarsounas   +7 more
core   +1 more source